Corcept Therapeutics, Inc. (CORT)

[Thurly]

Is Belanoff saying that in 2014 they will net revenue of $56.2M?

The press release said:

“Korlym® revenue increased 56 percent in the fourth quarter compared to the prior quarter,” said
K. Belanoff, MD, Corcept’s Chief Executive Officer. “We expect our momentum to continue in 2014,
with Korlym revenue reaching the $24 million to $28 million range for the year.”

If "our momentum" (56%) is to continue, 24-28M has to represent Q414 net revenue.

56% growth starting at $4.1M Q413 net revenue would equate to quarterly revenue in 2014 of:

6,396,000.00 Q1
9,977,760.00 Q2
15,565,305.60 Q3
24,281,876.74 Q4

A 457% growth rate.

Yes? Or maybe he's not being specific about the rate of growth, just that positive momentum will continue through 2014.